Cargando…
The development of anticholinergics in the management of COPD
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maxim...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692120/ https://www.ncbi.nlm.nih.gov/pubmed/18044064 |
_version_ | 1782167933145841664 |
---|---|
author | Scullion, Jane E |
author_facet | Scullion, Jane E |
author_sort | Scullion, Jane E |
collection | PubMed |
description | Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD. |
format | Text |
id | pubmed-2692120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26921202009-06-16 The development of anticholinergics in the management of COPD Scullion, Jane E Int J Chron Obstruct Pulmon Dis Review Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD. Dove Medical Press 2007-03 2007-03 /pmc/articles/PMC2692120/ /pubmed/18044064 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Scullion, Jane E The development of anticholinergics in the management of COPD |
title | The development of anticholinergics in the management of COPD |
title_full | The development of anticholinergics in the management of COPD |
title_fullStr | The development of anticholinergics in the management of COPD |
title_full_unstemmed | The development of anticholinergics in the management of COPD |
title_short | The development of anticholinergics in the management of COPD |
title_sort | development of anticholinergics in the management of copd |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692120/ https://www.ncbi.nlm.nih.gov/pubmed/18044064 |
work_keys_str_mv | AT scullionjanee thedevelopmentofanticholinergicsinthemanagementofcopd AT scullionjanee developmentofanticholinergicsinthemanagementofcopd |